Tempus AI widens Bristol Myers tie-up in oncology and AI data deal
Tempus AI and Bristol Myers Squibb extend their partnership through 2031, with $192.5 million in committed cash over five years, per Dow Jones.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Tempus AI has signed a multi-year agreement with Bristol Myers Squibb that gives the drugmaker licensed oncology data and access to Lens, its AI platform. The contract runs through 2031 and is intended to support biological research, the search for new drug targets and treatment development across Bristol Myers' cancer portfolio.
Separately, Pathos AI, a clinical-stage technology company, is broadening its collaborations with both Bristol Myers and Tempus. The three parties plan to build a curated dataset and agentic AI tools focused on Alzheimer's and other neurological conditions. Bristol Myers also led a $237 million Series E round for Pathos at a $3 billion valuation and gained rights to its Foundry AI platform.
A regulatory filing released Friday shows the arrangements give Tempus $192.5 million in total cash commitments over five years: $137.5 million from Bristol Myers and $55 million from Pathos AI in exchange for 500,000 de-identified patient records.
why it matters
Deals like this tie AI developers more closely to the research programs of large drugmakers, and the disclosed cash commitments give investors a concrete figure for the size of the contracts over time. For the broader market this is mainly company-level news, affecting one firm and a narrow segment of medical AI.
market impact
Tempus AI: multi-year Bristol Myers contracts add disclosed cash commitments for the company
tags
instruments
sources
- Tempus AI Expands Bristol Myers Partnership With Multi-Year Oncology, AI Data Deals — Dow Jones Newswires, 23 October 2026 at 14:16 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗